Atomic AI Adds Bristol Myers Squibb Veteran Dr. Manjunath Ramarao as Chief Scientific Officer
Atomic AI, a biotechnology company fusing cutting-edge machine learning with state-of-the-art structural biology to unlock RNA drug discovery, today announced the addition of Manjunath “Manju” Ramarao, Ph.D., as Chief Scientific Officer.
- Atomic AI, a biotechnology company fusing cutting-edge machine learning with state-of-the-art structural biology to unlock RNA drug discovery, today announced the addition of Manjunath “Manju” Ramarao, Ph.D., as Chief Scientific Officer.
- With over 20 years in the pharmaceutical industry, Dr. Ramarao brings extensive multidisciplinary experience in biopharmaceutical research and preclinical therapeutic development.
- We welcome Manju to the Atomic AI family!”
Prior to joining Atomic, Dr. Ramarao was Chief Scientific Officer at Ribometrix where he was responsible for enabling the company’s technology platform and establishing the pipeline of small molecule programs. - “Atomic AI has developed an impressive platform leveraging a sophisticated AI technology that is set to revolutionize the drug discovery and development paradigm,” said Dr. Ramarao.